Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$3.20 USD
+0.05 (1.59%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
RPTX 3.20 +0.05(1.59%)
Will RPTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RPTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RPTX
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
RPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why
Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a Turnaround
Other News for RPTX
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
Repare Therapeutics Announces Board Changes and FD Disclosure
Repare Therapeutics appoints Steven Stein to its board of directors
Buy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Outlook and Attractive Valuation
Repare Therapeutics reinstated with a Buy from Accumulate at Bloom Burton